La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Minerva Surgical Gestion

Gestion contrôle des critères 0/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Darrin Hammers

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	less than a year
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	less than a year
Durée moyenne du mandat des membres du conseil d'administration	1.6yrs

Mises à jour récentes de la gestion

Recent updates

Is There An Opportunity With Minerva Surgical, Inc.'s (NASDAQ:UTRS) 44% Undervaluation?

Aug 11

Minerva downgraded at JPMorgan citing lowered guidance

Aug 10

Minerva Surgical, Inc. (NASDAQ:UTRS) Just Reported Earnings, And Analysts Cut Their Target Price

Mar 10

Minerva Surgical - Uterine Play For Sale

Nov 02

PDG

Darrin Hammers

less than a year

Titularisation

Mr. Darrin Hammers is Chief Executive Officer of Minerva Surgical, Inc. from August 2024. He has certain years of leadership experience in the medical device industry and he has been President and Chief Ex...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Darrin Hammers	Chief Executive Officer	less than a year	pas de données	pas de données
Greg Simbro	Vice President of Finance	less than a year	pas de données	pas de données
Erik Reese	Vice President of Sales	less than a year	pas de données	pas de données
Wendy Bowman	Vice President of Human Resources	no data	pas de données	pas de données
Evgueni Skalnyi	Chief Medical Officer	1.7yrs	US$388.99k	pas de données
Joanne Long	Vice President of Corporate Controller	3.6yrs	pas de données	pas de données

0.7yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de UTRS n'est pas considérée comme expérimentée (ancienneté moyenne 1.1 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Uri Geiger	Director	1.6yrs	pas de données	pas de données
Catherine Coste	Independent Director	3.6yrs	US$187.50k	0.067% $ 0.005
Daniel Cohen	Independent Director	1.6yrs	pas de données	0% $ 0

1.6yrs

Durée moyenne de l'emploi

56yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de UTRS ne sont pas considérés comme expérimentés (ancienneté moyenne 1.5 ans), ce qui suggère un nouveau conseil d'administration.

Minerva Surgical Gestion

Gestion contrôle des critères 0/4

Informations clés

Mises à jour récentes de la gestion

Minerva Surgical, Inc. Announces the Resignation of Jill D. Anderson from the Board of Directors

Minerva Surgical, Inc. Announces Resignation of Ross A. Jaffe from the Board and from the Compensation Committee of the Board

High number of new directors

Minerva Surgical, Inc. Announces Resignation of David M. Renzi from Board of Directors and as Chairman of its Nominating and Corporate Governance Committee

Minerva Surgical, Inc. Announces Management Changes

Minerva Surgical, Inc. Appoints Derrick Sung as Director

Recent updates

Minerva Surgical Files Form 15

Minerva Surgical, Inc.(OTCPK:UTRS) dropped from NASDAQ Composite Index

Minerva Surgical, Inc. Announces Voluntary SEC Deregistration and Nasdaq Delisting

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Financial position

Minerva Surgical, Inc. Announces the Resignation of Jill D. Anderson from the Board of Directors

Minerva Surgical, Inc. announced that it expects to receive $20 million in funding from Accelmed Partners

Consensus EPS estimates upgraded to US$0.22 loss

Minerva Surgical, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Minerva Surgical, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Minerva Surgical, Inc. Announces Resignation of Ross A. Jaffe from the Board and from the Compensation Committee of the Board

Minerva Surgical Provides Revenue Guidance for the Full Year of 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings released: US$1.18 loss per share (vs US$3.06 loss in FY 2021)

Minerva Surgical, Inc. announced that it has received $30 million in funding from Accelmed Partners, New Enterprise Associates, Inc.

High number of new directors

Minerva Surgical, Inc. Announces Resignation of David M. Renzi from Board of Directors and as Chairman of its Nominating and Corporate Governance Committee

Minerva Surgical Receives Written Notice from Nasdaq Regarding Minimum Market Value of Publicly Held Shares

Minerva Surgical, Inc. Announces Management Changes

Minerva Surgical, Inc. announced that it expects to receive $30 million in funding from Accelmed Partners, New Enterprise Associates, Inc.

Consensus forecasts updated

Minerva Surgical, Inc. Provides Revenue Guidance for 2022

Third quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to US$5.00

Minerva Surgical Receives Notification Regarding Minimum Bid Price from the Listing Qualifications Department of the Nasdaq

Minerva Surgical, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Consensus forecasts updated

U.S. Court of Appeals for the Federal Circuit Affirms Ruling on Minerva Surgical, Inc. and Hologic, Inc. Case

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Is There An Opportunity With Minerva Surgical, Inc.'s (NASDAQ:UTRS) 44% Undervaluation?

Minerva downgraded at JPMorgan citing lowered guidance

Minerva Surgical, Inc. Revises Revenue Guidance for the Year 2022

Minerva Surgical, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Minerva Surgical, Inc. Appoints Derrick Sung as Director

Minerva Surgical, Inc.(NasdaqGM:UTRS) dropped from Russell Microcap Value Index

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Minerva Surgical, Inc. Provides Earnings Guidance for 2022

Minerva Surgical, Inc., Annual General Meeting, Jun 09, 2022

Minerva Surgical, Inc. Provides Revenue Guidance for the Full Year 2022

Minerva Surgical, Inc. (NASDAQ:UTRS) Just Reported Earnings, And Analysts Cut Their Target Price

Full year 2021 earnings: EPS exceeds analyst expectations

Minerva Surgical, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Minerva Surgical, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2021

President recently bought US$123k worth of stock

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Minerva Surgical, Inc. Provides Revenue Guidance for the Full Year 2021

Minerva Surgical - Uterine Play For Sale

PDG

Titularisation

Équipe de direction

Durée moyenne de l'emploi

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen